Trastuzumab biosimilar - Axxo
Latest Information Update: 24 Sep 2013
At a glance
- Originator AXXO
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Breast cancer
Most Recent Events
- 24 Sep 2013 Investigation in Breast cancer in Germany (IV)